Abstract 100P
Background
Colorectal cancer ranks as the third most prevalent cancer globally and stands as the second primary contributor to cancer-related mortality. Utilization of a phenomic data approach allows researchers to reveal the mechanisms and molecular pathogenesis of colorectal cancer. We aimed to investigate the correlation between the phenomic features and colorectal cancer in a large cohort study.
Methods
We included 502369 subjects aged 37-73 years in the UK Biobank recruited since 2006. In total, 59 parameters exploring socio-demographic factors, blood chemistry, anthropometric measurements and lifestyle factors of participants collected at baseline assessment were analysed. Univariate and multivariate logistic regression were conducted to examine the associations of these parameters with colorectal cancer risk, based on the odds ratio (OR) and 95% confidence intervals (CI).
Results
The analysis included a total of 438625 participants, of which 5436 (1.2%) were incident colorectal cancer cases and 433189 were healthy controls. A marker, cystatin C was associated with colorectal cancer (adjusted OR 2.11; 95% CI 1.92-2.32). Compared to Asians, Whites ethnicity had higher risk of developing colorectal cancers (adjusted OR 2.54; 95% CI 1.93-3.34). In addition to colorectal cancer, Cystatin C and ethnicity are consistently associated with total gastrointestinal cancers. Cystatin C and ethnicity appear to be important features in GI cancers, suggesting some overlap in the molecular pathogenesis of GI cancers.
Conclusions
Cystatin C and ethnicity emerged as a consistent biomarker associated with different types of gastrointestinal cancers, including colorectal cancer. In order to provide more in-depth understanding of how these factors were associated with gastrointestinal cancers and shed light on the molecular pathogenesis of gastrointestinal cancers, future research will employ a multi-modal approach exploring the genomics and proteomics of the UK Biobank cohort.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
228P - Real-world data on dose adjustment of cabozantinib in advanced renal cell carcinoma
Presenter: Hemavathi Baskarane
Session: Poster Display
Resources:
Abstract
229P - The application of diffusion kurtosis imaging in predicting muscle invasion of bladder cancer: A comparison with conventional DWI
Presenter: Shuai Jiang
Session: Poster Display
Resources:
Abstract
230P - Oncological outcomes between partial cystectomy and radical cystectomy in solitary muscle invasive bladder cancer with downgraded T stage
Presenter: Ming Wei Hsu
Session: Poster Display
Resources:
Abstract
231P - BMI-predicted progression-free survival after pembrolizumab therapy for urothelial cancer: Asian version of BMI classification is suitable for Asian patients
Presenter: mirii harada
Session: Poster Display
Resources:
Abstract
232P - The immunosuppressive features of the 20S Proteasome β-subunit gene family in von Hippel-Lindau (VHL)-mutated clear cell renal cell carcinoma (ccRCC): A TCGA-based bioinformatics study
Presenter: Saja Alzghoul
Session: Poster Display
Resources:
Abstract
233P - The crosstalk between PBRM1 loss and tumor immune microenvironment (TIME) of clear cell renal cell carcinoma (ccRCC): A possible interconnection to immunotherapy response
Presenter: Ahmed Al Sharie
Session: Poster Display
Resources:
Abstract
235P - Do FGFR2 and 3 proteins have a role in the prognosis of urothelial bladder carcinoma?
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
236P - The effects of chemotherapy on body composition in patients with advanced urothelial carcinoma
Presenter: KOSUKE KITAMURA
Session: Poster Display
Resources:
Abstract
237P - Real-world analysis of adjuvant nivolumab in resected urothelial cancer: A single institute study in Taiwanese patients
Presenter: Mu-Hsin Chang
Session: Poster Display
Resources:
Abstract
238P - Enfortumab-vedotin for metastatic urothelial carcinoma refractory to platinum-based chemotherapy and immune checkpoint inhibitors: A single institution experience
Presenter: Yuki Endo
Session: Poster Display
Resources:
Abstract